Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
The substantial progress made in the basic sciences of the brain has yet to be adequately translated to successful clinical therapeutics to treat central nervous system (CNS) diseases. Possible explanations include the lack of quantitative and validated biomarkers, the subjective nature of many clin...
Main Authors: | Hugo Geerts, John Wikswo, Piet H. van derGraaf, Jane P.F. Bai, Chris Gaiteri, David Bennett, Susanne E. Swalley, Edgar Schuck, Rima Kaddurah‐Daouk, Katya Tsaioun, Mary Pelleymounter |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12478 |
Similar Items
-
Pharmacometrics and/or Systems Pharmacology
by: Piet H. van derGraaf
Published: (2019-06-01) -
Metabolic profiling of patients with schizophrenia.
by: Rima Kaddurah-Daouk
Published: (2006-08-01) -
Salvaging CNS Clinical Trials Halted Due to COVID‐19
by: Hugo Geerts, et al.
Published: (2020-07-01) -
<it>ADDME – Avoiding Drug Development Mistakes Early</it>: central nervous system drug discovery perspective
by: Mabondzo Aloise, et al.
Published: (2009-06-01) -
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies
by: Peter Bloomingdale, et al.
Published: (2021-05-01)